Quality of life in patients with glioblastoma
https://doi.org/10.56618/2071-2693_2025_17_4_98
EDN: MQLTKW
Abstract
INTRODUCTION. Because patients with glioblastomas have a limited life expectancy and suffer from neurological, cognitive, and systemic symptoms caused by both the tumor itself and the treatment, an approach to assessing quality of life and its impact on survival is crucial for these patients.
AIM. To determine the differences in the quality of life of patients with glioblastomas after surgical treatment based on the QLQ-BN20 questionnaire, depending on the resection class according to the RANO-resect classification (2022), and their impact on survival.
MATERIALS AND METHODS. The study included 63 patients with IDH-wildtype glioblastomas. The RANO criteria (2022) were used to assess radicality. The QLQ-BN20 questionnaire was used to assess the quality of life before discharge, 1, 3, and 6 months after surgery.
RESULTS. The questionnaire indicators were analyzed depending on the resection class – motor disorders (p=0.039; p=0.019; p=0.009; p=0.005) and uncertainty about the future (p=0.013; p=0.013; p=0.023; p=0.030) differed at all stages of follow-up. When assessing epileptic seizures, differences were found after 6 months (p=0.021). At the second stage, an analysis of the impact of indicators on survival was carried out. Predictors of worsening survival were increased uncertainty about the future before discharge (p<0.001), after 1 (p<0.001), 3 (p<0.001) and 6 months (p< 0.001), motor disorders before discharge (p=0.023) and after 3 months (p=0.014), difficulties with communication before discharge (p=0.023) and after 1 month (p=0.008), weakness in the legs after 6 months (p=0.041) and drowsiness before discharge (p=0.007) and after 3 months (p=0.003).
CONCLUSION. Quality of life assessment using the QLQ-BN20 questionnaire is a useful tool for predicting outcomes in patients with glioblastomas that go beyond traditional oncological criteria.
About the Authors
K. A. Chizhova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Kseniia A. Chizhova – Neurosurgeon, Postgraduate Student at the Department of Neurosurgery
2 Akkuratova street, St. Petersburg, 197341
D. A. Gulyaev
Almazov National Medical Research Centre; North-Western State Medical University named after I. I. Mechnikov
Russian Federation
Russian Federation
Dmitry A. Gulyaev – Dr. of Sci. (Med.), Full Professor, Chief Researcher at Research Laboratory of Integrative Neurosurgical Technologies; Associate Professor at the Department of Neurosurgery
2 Akkuratova street, St. Petersburg, 197341
41 Kirochnaya street, St. Petersburg, 191015
V. Yu. Chirkin
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Vladislav Yu. Chirkin – Cand. of Sci. (Med.), Neurosurgeon, Head at the Department of Neurosurgery No. 5
2 Akkuratova street, St. Petersburg, 197341
I. A. Kurnosov
National Medical Research Center of Oncology named after N. N. Petrov
Russian Federation
Russian Federation
Ivan A. Kurnosov – Cand. of Sci. (Med.), Neurosurgeon, Head at the Department of Neurooncology
68 Leningradskaya street, village Pesochny, St. Petersburg, 197758
References
1. Kotecha R., Odia Y., Khosla A. A., Ahluwalia M. S. Key Clinical Principles in the Management of Glioblastoma. JCO Oncol Pract. 2023;19(4):180–189. Doi: 10.1200/OP.22.00476.
2. Wen P. Y., Macdonald D. R., Reardon D. A. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972. Doi: 10.1200/JCO.2009.26.3541.
3. Sipos D., Raposa B. L., Freihat O. et al. Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes. Cancers (Basel). 2025;17(1):146. Doi: 10.3390/cancers17010146.
4. Librizzi G., Lombardi G., Bertoldo A., et al. Perioperative imaging predictors of tumor progression and pseudoprogression: A systematic review. Crit Rev Oncol Hematol. 2024; 202: 104445. Doi: 10.1016/j.critrevonc.2024.104445.
5. Lucas C. G., Al-Adli N. N., Young J. S., et al. Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. Neuro Oncol. 2025;27 (1):89–105. Doi: 10.1093/neuonc/noae214.
6. Taylor K. R., Monje M. Invasive glioma cells: The malignant pioneers that follow the current. Cell. 2022;185(16):2846–2848. Doi: 10.1016/j.cell.2022.06.033.
7. Scheepens J. C. C., Taphoorn M. J. B., Koekkoek J. A. F. Patient-reported outcomes in neuro-oncology. Curr Opin Oncol. 2024;36(6):560–568. Doi: 10.1097/CCO.0000000000001078.
8. Osoba D., Aaronson N. K., Muller M. et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996;5(1):139–150. Doi: 10.1007/BF00435979.
9. Mauer M. E., Bottomley A., Taphoorn M. J. Evaluating health-related quality of life and symptom burden in brain tumour patients: instruments for use in experimental trials and clinical practice. Curr Opin Neurol. 2008;21(6):745–753. Doi: 10.1097/WCO.0b013e328315ef7d.
10. Karschnia P., Young J. S., Dono A. et al. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. Neuro Oncol. 2023;25(5):940–954. Doi: 10.1093/neuonc/noac193.
11. Cherebillo V. Yu., Kurnukhina M. Yu. Study of the quality of life of pat ients with cerebral glioma in the pre- and postoperative period. Onkologiya: Zhurnal im. P.A. Gertsena. 2020;9(2):37–41. (In Russ.)]. Doi: 10.17116/onkolog2020902137.
12. Mauer M., Stupp R., Taphoorn M. J. et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer. 2007;97(3):302–307. Doi: 10.1038/sj.bjc.6603876.
13. Paquette B., Vernerey D., Chauffert B. et al. Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma. Cancer Med. 2016;5(8):1753–1764. Doi: 10.1002/cam4.734.
14. Choudry U. K., Shaikh H. I., Nisar A. et al. Role of extent of resection on quality of life in patients with newly diagnosed GBM. J Pak Med Assoc. 2018;68(1):142–144.
15. Daigle K., Fortin D., Mathieu D. et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed patients with glioblastoma: a report on 19 patients surviving to follow-up. Curr Med Res Opin. 2013;2(10): 1307–1313. Doi: 10.1185/03007995.2013.823858.
16. Bjorland L. S., Mahesparan R., Fluge Ø. et al. Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study. Neurooncol Adv. 2023;5(1): vdad126. Doi: 10.1093/noajnl/vdad126.
17. Tropeano M. P., Raspagliesi L., Bono B. C. et al. Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification. Acta Neurochir (Wien). 2024;166(1):196. Doi: 10.1007/s00701-024-06090-2.
18. Luque L., Skogen K., MacIntosh B. J. et al. Standardized evaluation of the extent of resection in glioblastoma with automated early post-operative segmentation. Front Radiol. 2024;(4):1357341. Doi: 10.3389/fradi.2024.1357341.
19. Chaichana K. L., Chaichana K. K., Olivi A. et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg. 2011;114(3):587–594. Doi: 10.3171/2010.8.JNS1081.
20. McGirt M. J., Mukherjee D., Chaichana K. L. et al. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery. 2009;65(3):463–470. Doi: 10.1227/01.NEU.0000349763.42238.E9.
21. Rozumenko V. D., Khoroshun A. P. Parameters of life quality in the treatment efficiency estimation of patients with glial brain tumors. Ukrainian Neurosurgical Journal. 2007;(1):26–31.(In Russ.).
Review
For citations:
Chizhova K.A., Gulyaev D.A., Chirkin V.Yu., Kurnosov I.A. Quality of life in patients with glioblastoma. Russian Neurosurgical Journal named after Professor A. L. Polenov. 2025;17(4):98-106. (In Russ.) https://doi.org/10.56618/2071-2693_2025_17_4_98. EDN: MQLTKW
Views:
133
JATS XML
Email this article 